Life sciences company Revvity (NYSE: RVTY) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 7% year on year to $711.1 million. On the other hand, the company’s full-year revenue guidance of $2.83 billion at the midpoint came in 5.2% below analysts’ estimates. Its non-GAAP profit of $1.06 per share was 4.5% above analysts’ consensus estimates.

Is now the time to buy Revvity? Find out by accessing our full research report, it’s free.

“We performed well in the first quarter, with organic growth and adjusted EPS exceeding our expectations, reflecting strong execution from our teams across the organization,” said Prahlad Singh, president and chief executive officer of Revvity.

Company Overview

Formerly known as PerkinElmer until its rebranding in 2023, Revvity (NYSE: RVTY) provides health science technologies and services that support the complete workflow from discovery to development and diagnosis to cure.

Revenue Growth

A company’s long-term performance is an indicator of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Revvity struggled to consistently generate demand over the last five years as its sales dropped at a 8.2% annual rate. This wasn’t a great result and is a sign of poor business quality.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Revvity’s annualized revenue growth of 3.2% over the last two years is above its five-year trend, which is encouraging.

We can dig further into the company’s sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don’t accurately reflect its fundamentals. Over the last two years, Revvity’s organic revenue averaged 2.9% year-on-year growth. Because this number aligns with its two-year revenue growth, we can see the company’s core operations (not acquisitions and divestitures) drove most of its results.

This quarter, Revvity reported year-on-year revenue growth of 7%, and its $711.1 million of revenue exceeded Wall Street’s estimates by 0.8%.

Looking ahead, sell-side analysts expect revenue to grow 3.7% over the next 12 months, similar to its two-year rate. This projection doesn't excite us and suggests its newer products and services will not lead to better top-line performance yet.

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

Adjusted Operating Margin

Revvity has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average adjusted operating margin of 29.8%.

Analyzing the trend in its profitability, Revvity’s adjusted operating margin decreased by 9.8 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 3.7 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.

In Q1, Revvity generated an adjusted operating margin profit margin of 11.9%, down 13.7 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.

Earnings Per Share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.

Sadly for Revvity, its EPS declined by 14.7% annually over the last five years, more than its revenue. This tells us the company struggled because its fixed cost base made it difficult to adjust to shrinking demand.

We can take a deeper look into Revvity’s earnings to better understand the drivers of its performance. As we mentioned earlier, Revvity’s adjusted operating margin declined by 9.8 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q1, Revvity reported adjusted EPS of $1.06, up from $1.01 in the same quarter last year. This print beat analysts’ estimates by 4.5%. Over the next 12 months, Wall Street expects Revvity’s full-year EPS of $5.12 to grow 11.5%.

Key Takeaways from Revvity’s Q1 Results

It was good to see Revvity narrowly top analysts’ organic revenue expectations this quarter. We were also glad its EPS outperformed Wall Street’s estimates. On the other hand, its full-year revenue guidance missed and its full-year EPS guidance fell short of Wall Street’s estimates. Overall, this was a weaker quarter. The stock traded up 2.2% to $88.42 immediately after reporting.

So should you invest in Revvity right now? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here (it’s free).